PDE4A and early-onset autosomal dominant Alzheimer disease: Inhibition of the major cyclic adenosine monophosphate (AMP)-metabolizing enzyme PDE4 has shown a potential for the discovery of drugs for cancer, inflammation, and neurodegenerative disorders such as Alzheimer’s disease.